Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

Omalizumab biosimilar is under clinical development by Mabpharm and currently in Phase III for Chronic Urticaria Or Hives.

Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile ...

Analyst Silvan Tuerkcan of JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report), with a price target of $3.00.Stay Ahead ...

Kwatra: Chronic spontaneous urticaria — that's a mouthful ... practitioner when even talking about this disease, let alone treatment options? Kwatra: The number-one thing the patients want ...

"I am excited to see the preliminary clinical data which demonstrated that treatment with briquilimab ... additional studies of briquilimab in chronic urticaria." "We are very pleased to present ...

The duration of CU is also unpredictable and disease control is often suboptimal, especially when treatment is inadequate. Chronic urticaria has a significant impact on work, even when it is well ...

Citi keeps a Buy rating on Celldex (CLDX) with a $70 price target after after Jasper Therapeutics (JSPR) reported preliminary data from its ...

Despite positive preliminary data from its early stage study of treating hives, Jasper Therapeutics Inc. saw its stock drop dramatically on Jan. 8. Results were from the ongoing phase Ib/IIa study of ...

Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritin ...

The batch of Montek-LC Tablets (Montelukast Sodium and Levocetirizine Hydrochloride Tablets) seized by the TSDCA were ...